MARKET

ORGS

ORGS

Orgenesis Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.860
-0.200
-3.95%
After Hours: 4.860 0 0.00% 16:41 05/17 EDT
OPEN
4.970
PREV CLOSE
5.06
HIGH
5.07
LOW
4.800
VOLUME
151.15K
TURNOVER
--
52 WEEK HIGH
8.30
52 WEEK LOW
4.140
MARKET CAP
118.97M
P/E (TTM)
-1.2601
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 3d ago
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 4d ago
64 Biggest Movers From Yesterday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 82.6% to settle at $6.39 on Monday.
Benzinga · 6d ago
40 Stocks Moving In Monday's Mid-Day Session
Gainers Protagenic Therapeutics, Inc. (NASDAQ: PTIX) shares jumped 64.2% to $3.4962 on above-average news.
Benzinga · 05/10 16:02
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 05/10 12:09
20 Stocks Moving in Monday's Pre-Market Session
Gainers Alfi, Inc. (NASDAQ: ALF) shares rose 30.3% to $4.82 in pre-market trading. The company recently appointed Ron Spears as Chief Revenue Officer.
Benzinga · 05/10 11:03
70 Biggest Movers From Friday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday.
Benzinga · 05/10 09:24
Proactive news headlines including Power Reit, Delta 9 Cannabis, Bragg Gaming and Acasti Pharma
New York, May 07, May 07, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, May 07, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video...
GlobeNewswire · 05/07 17:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ORGS. Analyze the recent business situations of Orgenesis Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ORGS stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 5.59M
% Owned: 22.84%
Shares Outstanding: 24.48M
TypeInstitutionsShares
Increased
12
427.69K
New
2
11.84K
Decreased
5
112.31K
Sold Out
2
745.48K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Chief Executive Officer/Director
Vered Caplan
Chief Financial Officer/Treasurer/Secretary
Neil Reithinger
Corporate Executive
Denis Bedoret
Corporate Executive
Darren Head
Chief Scientific Officer
Sarah Ferber
Independent Director
Yaron Adler
Independent Director
Ashish Nanda
Independent Director
Mario Philips
Independent Director
David Sidransky
Independent Director
Guy Yachin
No Data
About ORGS
Orgenesis Inc. is a biopharmaceutical company. The Company is developing, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates a point-of-care (POCare) cell therapy platform (POC). The POC platform develops Advanced Therapy Medicinal Products (ATMPs) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patient. The POC platform include a multitude of cell therapies, including autoimmune, oncologic, neurologic and metabolic diseases and other indications.

Webull offers kinds of Orgenesis Inc stock information, including NASDAQ:ORGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORGS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORGS stock methods without spending real money on the virtual paper trading platform.